Keros Therapeutics (KROS) Payables (2019 - 2026)

Keros Therapeutics (KROS) has reported Payables for 8 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 65.52% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (down 65.52% YoY), and the FY2025 full-year result was $2.0 million, down 57.26% from the prior year.
• Payables slipped to $1.8 million in Q2 2026 per KROS's latest filing, from $2.0 million in the prior quarter.
• Across five years, Payables topped out at $7.7 million in Q2 2022 and bottomed at $1.8 million in Q2 2026.
• Historically, Payables has averaged $4.4 million across 5 years, with a median of $4.6 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Payables soared 458.31% in 2022, then tumbled 65.52% in 2026.
• Over 5 years, Payables stood at $3.3 million in 2022, then soared by 63.22% to $5.4 million in 2023, then declined by 15.56% to $4.6 million in 2024, then slumped by 57.26% to $2.0 million in 2025, then decreased by 7.68% to $1.8 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $1.8 million, $2.0 million, and $2.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.